One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

Daniel B. Brown, Carin F. Gonsalves, Charles J. Yeo, Agnes K. Witkiewicz, Brian I. Carr

Research output: Contribution to journalArticle

Abstract

While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

Original languageEnglish
Pages (from-to)767-769
Number of pages3
JournalOncology Reports
Volume24
Issue number3
DOIs
Publication statusPublished - Sep 2010

Keywords

  • Chemoembolization
  • Gemcitabine
  • Pancreatic carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin'. Together they form a unique fingerprint.

  • Cite this